| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Agomab Therapeutics NV
13G
AGMB · 00860C102
|
6.8% |
4/16/2026
Event 3/31/2026
|
|||
| Pontifax VI G.P. L.P. | 6.8% | ||||
| Pontifax Management 4 G.P. (2015) Ltd. | 6.8% | ||||
| Ran Nussbaum | 6.8% | ||||
| Tomer Kariv | 6.8% | ||||
|
Keros Therapeutics, Inc.
13D/A
Amendment 2
KROS · 492327101
|
0% |
10/16/2025
Event 10/15/2025
|
|||
| Pontifax Management 4 GP (2015) Ltd. | 0% | ||||
| Pontifax (Israel) IV, L.P. | 0% | ||||
| Pontifax (Cayman) IV, L.P. | 0% | ||||
| Pontifax (China) IV, L.P. | 0% | ||||
| Pontifax Late Stage Fund L.P. | 0% | ||||
| Pontifax Late Stage GP Ltd. | 0% | ||||
|
LB Pharmaceuticals Inc
13D
LBRX · 50180M108
|
6.3% |
9/25/2025
Event 9/12/2025
|
|||
| Pontifax Management 4 G.P. (2015) Ltd. | 6.3% | ||||
| Pontifax VI G.P. L.P. | 6.3% | ||||
| Ran Nussbaum | 6.3% | ||||
| Tomer Kariv | 6.3% | ||||
|
Climb Bio, Inc.
13G
CLYM · 28658R106
|
7.7% |
9/18/2025
Event 6/27/2024
|
|||
| Pontifax VI G.P. L.P. | 7.7% | ||||
| Pontifax Management 4 G.P. (2015) Ltd. | 7.7% | ||||
| Ran Nussbaum | 7.7% | ||||
| Tomer Kariv | 7.7% | ||||
|
Keros Therapeutics, Inc.
13D/A
Amendment 1
KROS · 492327101
|
11.8% |
4/18/2025
Event 4/17/2025
|
|||
| Pontifax Management 4 GP (2015) Ltd. | 11.8% | ||||
| Pontifax (Israel) IV, L.P. | 5.6% | ||||
| Pontifax (Cayman) IV, L.P. | 2.8% | ||||
| Pontifax (China) IV, L.P. | 3.0% | ||||
| Pontifax Late Stage Fund L.P. | 0.4% | ||||
| Pontifax Late Stage GP Ltd. | 0.4% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.